Related Experiment Video
Updated: Sep 12, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Long-Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National
Angela Y Higgins1, Sarah Zimmerman2,3, Yongfei Wang2,3
1Department of Cardiovascular Medicine Maine Medical Center Portland ME USA.
Insights
Left atrial appendage occlusion (LAAO) effectively prevents stroke in atrial fibrillation patients. Long-term data shows low stroke rates but high mortality in elderly individuals, emphasizing personalized care decisions.
Area of Science:
- Cardiology
- Medical Devices
- Public Health
Background:
- Percutaneous left atrial appendage occlusion (LAAO) offers an alternative to anticoagulation for stroke prevention in atrial fibrillation.
- Limited long-term outcomes data exists for real-world LAAO patient populations.
Purpose of the Study:
- To evaluate long-term stroke rates and all-cause mortality in elderly patients undergoing LAAO with a WATCHMAN device.
- To assess the durability of LAAO for stroke prevention in a real-world setting.
Main Methods:
- Retrospective cohort study using the National Cardiovascular Data Registry LAAO registry (2016-2019).
- Linked LAAO data with Medicare claims for patients aged 65+ receiving WATCHMAN device.
- Primary outcomes: any stroke and all-cause mortality.
Main Results:
- Included 34,975 patients with a high mean CHA 2 DS 2 -VASc score (4.7±1.4).
- 1-year and 5-year stroke estimates were 1.70% and 5.70%, respectively.
- 5-year mortality estimate was 44.34% in this elderly cohort.
Conclusions:
- Long-term stroke rates after LAAO are low and consistent in Medicare patients, even with high thromboembolic risk.
- High mortality rates highlight the need for shared decision-making, incorporating patient values and preferences.
Background:
Percutaneous left atrial appendage occlusion (LAAO) is an alternative to long-term anticoagulation for preventing ischemic stroke in patients with atrial fibrillation. There are limited long-term outcomes data for "real-world" patients undergoing LAAO.
Methods:
We performed a retrospective cohort study using the National Cardiovascular Data Registry LAAO registry from January 1, 2016, through December 31, 2019. We linked LAAO data to inpatient Medicare fee-for-service claims data using probabilistic matching to establish a cohort of patients 65 years and older undergoing LAAO with a WATCHMAN device. The primary outcomes were any stroke and all-cause mortality.
Results:
A total of 34 975 patients with a mean±SD CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) score of 4.7±1.4 were included. The median follow-up was 2.8 years (interquartile range, 2.2-3.7 years). The cumulative incidence of any stroke was 1.57 per 100 person-years (95% CI, 1.45-1.70), with a 1-year and 5-year any stroke estimate of 1.70% (95% CI, 1.57-1.84%) and 5.70% (95% CI, 5.37-6.05%), respectively. The cumulative incidence of ischemic stroke was 1.36 per 100 person-years (95% CI, 1.25-1.48), with a 1-year and 5-year ischemic stroke estimate of 1.42% (95% CI, 1.30-1.54%) and 5.03% (95% CI, 4.71-5.36%), respectively. The cumulative incidence of death was 10.82 per 100 person-years (95% CI, 10.49-11.13), with a 5-year mortality estimate of 44.34% (95% CI, 43.35-45.23%).
Conclusions:
Long-term stroke rates in a large nationally representative cohort of Medicare patients following LAAO were low and durably consistent during long-term follow-up despite a high thromboembolic risk. High mortality rates in this elderly population underscore the importance of incorporating patient values and preferences when considering LAAO.
Related Concept Videos
Mitral Stenosis III: Medical Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Mitral Regurgitation III: Medical Management

